Document is current
Any future updates will be listed below
-
Authors
Rimini, Margherita
Fabregat-Franco, Carles
Burgio, Valentina
Lonardi, Sara
Niger, Monica
Scartozzi, Mario
Rapposelli, Ilario Giovanni
Aprile, Giuseppe
Ratti, Francesca
Pedica, Federica
Verdaguer, Helena
Rizzato, Mario
Nichetti, Federico
Lai, Eleonora
Cappetta, Alessandro
Macarulla, Teresa
Fassan, Matteo
De Braud, Filippo
Pretta, Andrea
Simionato, Francesca
De Cobelli, Francesco
Aldrighetti, Luca
Fornaro, Lorenzo
Cascinu, Stefano
Casadei-Gardini, Andrea
- License Information
-
More Information
Article History
Received: 18 July 2022
Accepted: 17 October 2022
First Online: 5 November 2022
Competing interests
: MN: Travel expenses from Celgene, speaker honorarium from Accademia della Medicina. Consultant honoraria from EMD Serono, Basilea Pharmaceutica, Incyte and MSD Italia. FdB: Honoraria from Roche, Pfizer, BMS, Merck, MSD, SERVIER, Sanofi, Amgen Astellas BioPharma, Incyte. Consulting or Advisory Role for Roche, Incyte, EMD Serono, BMS, Nerviano Medical Sciences, Sanofi, Novartis Italy, Menarini, research funding (institution): Novartis, Roche, Merck Serono, Pfizer, Servier, Philogen, Loxo, Tesaro, Nerviano Medical Sciences, Kymab. Research funding: BMS/Medarex, Merck KGaA, Ignyta, MedImmune, Exelis, Bayer health, Daiichi Sangyo Europe GmbH, Incyte, Basilea Pharmaceutical, jassen Oncology. TM: (SOBI) Swedish Orpahn Biovitrum AB, Ability Pharmaceuticals SL, Aptitude Health, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Ellipses, Genzyme, Got It Consulting SL, Hirslanden/GITZ, Imedex, Incyte, Ipsen Bioscience , Inc, Janssen, Lilly. Marketing Farmacéutico & Investigación Clínica, S.L, MDS, Medscape, Novocure, Paraxel, PPD Development, Polaris, QED Therapeutics, Roche Farma, Sanofi-Aventis, Servier, Scilink Comunicación Científica SC, Surface Oncology, and Zymeworks. All other authors declare no competing interests.
